FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199651111> ?p ?o ?g. }

• W3199651111 endingPage "2686" @default.
• W3199651111 startingPage "2676" @default.
• W3199651111 abstract "Several cardiovascular outcome trials on sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been released recently, including trials enrolling patients with congestive heart failure (CHF) and chronic kidney disease (CKD). Comparisons of the efficacy and safety of SGLT2i, glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) thus require an update. Assessments in patient subgroups, i.e., as stratified by age or the presence of CHF, CKD or atherosclerotic cardiovascular disease (ASCVD), are also currently lacking. We searched the PubMed, Embase and Cochrane databases for relevant studies published up until 5 December 2020. RCTs comparing SGLT2i, GLP-1RA and DPP-4i with placebo (or other controls) or with each other with cardiovascular (CV) or renal outcomes were eligible for inclusion. The primary efficacy endpoint was 3-point major adverse cardiovascular events (3P-MACE), which are defined as CV death, non-fatal myocardial infarction and non-fatal ischaemic stroke. All-cause mortality, hospitalisation for heart failure (HHF) and composite renal outcomes were also analysed. Pre-specified subgroup analyses of 3P-MACE were also performed. A total of 21 trials with 170,930 participants were included in this network meta-analysis. Both GLP-1RA and SGLT2i were associated with lower risks of 3P-MACE than placebo (RR 0.89, 95% CI 0.84, 0.94 and RR 0.88, 95% CI 0.83, 0.94, respectively). GLP-1RA and SGLT2i were also associated with lower risks of 3P-MACE than DPP-4i (RR 0.89, 95% CI 0.82, 0.98 and RR 0.89, 95% CI 0.81, 0.97, respectively). A comparison between SGLT2i and GLP-1RA demonstrated no difference in their risks of 3P-MACE (RR 0.99, 95% CI 0.91, 1.08). Only GLP-1RA was associated with a lower risk of stroke compared with placebo (RR 0.85, 95% CI 0.76, 0.94). SGLT2i is superior to GLP-1RA in reducing HHF (RR 0.76, 95% CI 0.68, 0.84) and renal outcomes (RR 0.78, 95% CI 0.65, 0.93). Subgroup analyses indicated that the benefits of SGLT2i and GLP-1RA were more pronounced in elderly patients, white and Asian patients, those with established ASCVD and those with longer durations of diabetes mellitus and worse glycaemic control. SGLT2i and GLP-1RA are superior to DPP-4i in terms of CV and renal outcomes. GLP-1RA is the only drug class that reduces the risk of stroke. SGLT2i is superior in reducing HHF and renal outcomes. Therefore, the choice between SGLT2i and GLP-1RA should be individualised according to patient profiles. CRD42020206600." @default.
• W3199651111 created "2021-09-27" @default.
• W3199651111 creator A5001948295 @default.
• W3199651111 creator A5008828646 @default.
• W3199651111 creator A5022214679 @default.
• W3199651111 creator A5026722421 @default.
• W3199651111 date "2021-09-18" @default.
• W3199651111 modified "2023-10-13" @default.
• W3199651111 title "The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials" @default.
• W3199651111 cites W2001122065 @default.
• W3199651111 cites W2040557955 @default.
• W3199651111 cites W2063489619 @default.
• W3199651111 cites W2097575918 @default.
• W3199651111 cites W2098082628 @default.
• W3199651111 cites W2126919962 @default.
• W3199651111 cites W2146264128 @default.
• W3199651111 cites W2200657718 @default.
• W3199651111 cites W2282578582 @default.
• W3199651111 cites W2324267781 @default.
• W3199651111 cites W2329117883 @default.
• W3199651111 cites W2425644022 @default.
• W3199651111 cites W2519510391 @default.
• W3199651111 cites W2598820390 @default.
• W3199651111 cites W2613275687 @default.
• W3199651111 cites W2626446274 @default.
• W3199651111 cites W2766617433 @default.
• W3199651111 cites W2804105986 @default.
• W3199651111 cites W2894567505 @default.
• W3199651111 cites W2894746763 @default.
• W3199651111 cites W2900413769 @default.
• W3199651111 cites W2916296804 @default.
• W3199651111 cites W2948612418 @default.
• W3199651111 cites W2971147579 @default.
• W3199651111 cites W2974260792 @default.
• W3199651111 cites W2990869853 @default.
• W3199651111 cites W3003299879 @default.
• W3199651111 cites W3017015779 @default.
• W3199651111 cites W3037508799 @default.
• W3199651111 cites W3049708096 @default.
• W3199651111 cites W3081830235 @default.
• W3199651111 cites W3088173406 @default.
• W3199651111 cites W3089283105 @default.
• W3199651111 cites W3100542962 @default.
• W3199651111 cites W3101044784 @default.
• W3199651111 cites W4206445899 @default.
• W3199651111 cites W4232314044 @default.
• W3199651111 doi "https://doi.org/10.1007/s00125-021-05529-w" @default.
• W3199651111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34536085" @default.
• W3199651111 hasPublicationYear "2021" @default.
• W3199651111 type Work @default.
• W3199651111 sameAs 3199651111 @default.
• W3199651111 citedByCount "38" @default.
• W3199651111 countsByYear W31996511112021 @default.
• W3199651111 countsByYear W31996511112022 @default.
• W3199651111 countsByYear W31996511112023 @default.
• W3199651111 crossrefType "journal-article" @default.
• W3199651111 hasAuthorship W3199651111A5001948295 @default.
• W3199651111 hasAuthorship W3199651111A5008828646 @default.
• W3199651111 hasAuthorship W3199651111A5022214679 @default.
• W3199651111 hasAuthorship W3199651111A5026722421 @default.
• W3199651111 hasBestOaLocation W31996511111 @default.
• W3199651111 hasConcept C126322002 @default.
• W3199651111 hasConcept C127413603 @default.
• W3199651111 hasConcept C134018914 @default.
• W3199651111 hasConcept C142724271 @default.
• W3199651111 hasConcept C203092338 @default.
• W3199651111 hasConcept C204787440 @default.
• W3199651111 hasConcept C27081682 @default.
• W3199651111 hasConcept C2777180221 @default.
• W3199651111 hasConcept C2778198053 @default.
• W3199651111 hasConcept C2780400711 @default.
• W3199651111 hasConcept C2780533449 @default.
• W3199651111 hasConcept C2780645631 @default.
• W3199651111 hasConcept C2780739214 @default.
• W3199651111 hasConcept C44249647 @default.
• W3199651111 hasConcept C500558357 @default.
• W3199651111 hasConcept C535046627 @default.
• W3199651111 hasConcept C555293320 @default.
• W3199651111 hasConcept C71924100 @default.
• W3199651111 hasConcept C78519656 @default.
• W3199651111 hasConcept C82789193 @default.
• W3199651111 hasConcept C95190672 @default.
• W3199651111 hasConceptScore W3199651111C126322002 @default.
• W3199651111 hasConceptScore W3199651111C127413603 @default.
• W3199651111 hasConceptScore W3199651111C134018914 @default.
• W3199651111 hasConceptScore W3199651111C142724271 @default.
• W3199651111 hasConceptScore W3199651111C203092338 @default.
• W3199651111 hasConceptScore W3199651111C204787440 @default.
• W3199651111 hasConceptScore W3199651111C27081682 @default.
• W3199651111 hasConceptScore W3199651111C2777180221 @default.
• W3199651111 hasConceptScore W3199651111C2778198053 @default.
• W3199651111 hasConceptScore W3199651111C2780400711 @default.
• W3199651111 hasConceptScore W3199651111C2780533449 @default.
• W3199651111 hasConceptScore W3199651111C2780645631 @default.
• W3199651111 hasConceptScore W3199651111C2780739214 @default.
• W3199651111 hasConceptScore W3199651111C44249647 @default.
• W3199651111 hasConceptScore W3199651111C500558357 @default.
• W3199651111 hasConceptScore W3199651111C535046627 @default.

• next